195 related articles for article (PubMed ID: 2573640)
21. Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer.
Chen ZQ; Huang LS; Zhu B
Dis Markers; 2018; 2018():9845123. PubMed ID: 30647803
[TBL] [Abstract][Full Text] [Related]
22. [Serodiagnostic tests by factor analysis and stepwise discriminating analysis with tumor markers for the detection of ovarian cancer].
Kobayashi H; Sumimoto K; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1903-10. PubMed ID: 2480396
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer.
Bian J; Li B; Kou XJ; Liu TZ; Ming L
Asian Pac J Cancer Prev; 2013; 14(11):6241-3. PubMed ID: 24377511
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of tumor markers and their clinical significance in epithelial ovarian cancer.
Shan D; Cheng S; Ma Y; Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jul; 48(7):1039-1049. PubMed ID: 37724407
[TBL] [Abstract][Full Text] [Related]
25. [Usefulness of determining tumor markers CEA, CA125 and CA72-4 in blood serum of patients with ovarian carcinoma].
Kokocińska D; Worwag J; Tomala J; Dzieciuchowicz L; Nowak S; Kuśmierski S
Ginekol Pol; 1994 Sep; 65(9):495-501. PubMed ID: 7721162
[TBL] [Abstract][Full Text] [Related]
26. [Evaluation of CEA, SLX and CA125 in active pulmonary tuberculosis].
Ichiki H; Shishido M; Nishitani K; Takatsugi K; Nishiyama S; Yano M; Watanabe K
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31(12):1522-7. PubMed ID: 7907156
[TBL] [Abstract][Full Text] [Related]
27. [Clinical evaluation of serum sialyl Lewis X-i (SLX) in diffuse panbronchiolitis].
Noguchi M; Nakatani T; Chohnabayashi N; Nakamori Y; Nakata K; Matsushita H; Tanimoto H
Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Mar; 27(3):317-25. PubMed ID: 2575680
[TBL] [Abstract][Full Text] [Related]
28. [Clinical evaluation of serum sialyl SSEA-1 (SLX) in diagnosis of cancers].
Kawakami H; Sawabu N; Takemori Y; Okai T; Motoo Y; Satomura Y; Ohta H; Watanabe H; Matsuda N; Yamakawa O
Nihon Shokakibyo Gakkai Zasshi; 1989 May; 86(5):1141-8. PubMed ID: 2571740
[TBL] [Abstract][Full Text] [Related]
29. [Relationship between tumor markers and clinical symptoms in ovarian cancer].
Yakushiji M; Nishimura H
Rinsho Byori; 1992 Apr; 40(4):354-8. PubMed ID: 1593760
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination.
Emoto S; Ishigami H; Yamashita H; Yamaguchi H; Kaisaki S; Kitayama J
Gastric Cancer; 2012 Apr; 15(2):154-61. PubMed ID: 21892754
[TBL] [Abstract][Full Text] [Related]
31. [Value of SLX and CA19-9 in the serum and tissue in colorectal cancer including the relation to Lewis blood type].
Igarashi K
Nihon Shokakibyo Gakkai Zasshi; 1989 Oct; 86(10):2394-403. PubMed ID: 2574243
[TBL] [Abstract][Full Text] [Related]
32. [Significance of tumor markers in the treatment of patients with ovarian malignancies].
Tomoda Y; Kano T; Furuhashi Y; Mizuno K; Kamiya N; Mizuno K; Sakakibara K; Ohta M
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3027-33. PubMed ID: 2445293
[TBL] [Abstract][Full Text] [Related]
33. [Field trial for the early detection of patients with ovarian cancer].
Kobayashi H; Terao T
Rinsho Byori; 1992 Feb; 40(2):139-45. PubMed ID: 1374818
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of the number of positive tumor markers in assisting the diagnosis of lung cancer with multiple tumor marker assay.
Mizushima Y; Hirata H; Izumi S; Hoshino K; Konishi K; Morikage T; Maruyama M; Yamashita N; Yano S
Oncology; 1990; 47(1):43-8. PubMed ID: 2300384
[TBL] [Abstract][Full Text] [Related]
35. CA72-4: a new tumour marker for gastric cancer.
Byrne DJ; Browning MC; Cuschieri A
Br J Surg; 1990 Sep; 77(9):1010-3. PubMed ID: 2207563
[TBL] [Abstract][Full Text] [Related]
36. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients.
Fioretti P; Gadducci A; Ferdeghini M; Prontera C; Malagnino G; Facchini V; Mariani G; Bianchi R
Gynecol Oncol; 1992 Feb; 44(2):155-60. PubMed ID: 1544592
[TBL] [Abstract][Full Text] [Related]
37. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
[TBL] [Abstract][Full Text] [Related]
38. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis.
Gadducci A; Ferdeghini M; Prontera C; Moretti L; Mariani G; Bianchi R; Fioretti P
Gynecol Oncol; 1992 Feb; 44(2):147-54. PubMed ID: 1312052
[TBL] [Abstract][Full Text] [Related]
39. Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
Fukazawa I; Inaba N; Ota Y; Sato N; Shirotake S; Iwasawa H; Sekiya S; Takamizawa H; Suzuki N; Tokita H
Arch Gynecol Obstet; 1988; 243(2):69-81. PubMed ID: 3165255
[TBL] [Abstract][Full Text] [Related]
40. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
